Oncimmune Holdings PLC (LON:ONC) has revealed that its ImmunoINSIGHTS team played an important role in a study that “significantly expanded” the biomarkers commonly measured in rheumatoid arthritis (RA) patients.
The results, published in the peer-reviewed PLOS ONE scientific journal, also helped to develop a detailed picture of the immune response to the disease and its treatment.
Researchers from Oncimmune, drug giant Roche and University Medical Center Utrecht analysed auto-antibodies in patients with newly diagnosed RA who were treated with either Tocilizumab or Methotrexate.
Successful validation of a completely new autoantibody panel that is predictive of treatment response would be a major step forward in the management of this debilitating disease of the joints, Oncimmune said.
The company’s chief executive, Adam Hill, added that the work also clearly demonstrated the power of its SeroTag discovery platform in identifying biomarkers able to predict response to a selection of treatments for RA.
“This predictive capability presents an opportunity to develop and validate novel autoantibody panels for patient stratification in trials and the clinic,” he added in a statement.
For more information click here.